Trial
NCT04603365
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
BeiGene; Driven To Cure
Condition
Clear Cell Papillary Renal Neoplasm
Intervention
Pamiparib
Why stopped
enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-17